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the exposure was terminated (during the post-exposure 
period). The neutrophil number observed in bronchoalveo-
lar lavage fluid (BALF) was decreasing and supplemented 
by mononuclear cells, especially macrophages which were 
visible in histopathology but not in BALF. Further progres-
sion to granulomatous inflammation was observed 4 weeks 
post-exposure. The surface area of the particles provided 
a dose metrics with the best correlation of the two Ceria’s 
inflammatory responses; hence, the inflammation appears 
to be directed by the particle surface rather than mass or 
volume in the lung. Observing the time course of lung 
burden and inflammation, it appears that the dose rate of 
particle deposition drove an initial inflammatory reaction 
by neutrophils. The later phase (after 4 weeks) was domi-
nated by mononuclear cells, especially macrophages. The 
progression toward the subsequent granulomatous reaction 
was driven by the duration and amount of the particles in 
the lung. The further progression of the biological response 
will be determined in the ongoing long-term study.
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BALT  Bronchus-associated lymphoid tissue
BET  Brunauer–Emmet–Teller
Ceria  Cerium dioxide
CINC  Cytokine-induced neutrophil chemoattractant
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Abstract Two Ceria nanomaterials (NM-211 and 
NM-212) were tested for inhalation toxicity and organ 
burdens in order to design a chronic and carcinogenicity 
inhalation study (OECD TG No. 453). Rats inhaled aero-
sol concentrations of 0.5, 5, and 25 mg/m3 by whole-body 
exposure for 6 h/day on 5 consecutive days for 1 or 4 weeks 
with a post-exposure period of 24 or 129 days, respectively. 
Lungs were examined by bronchoalveolar lavage and his-
topathology. Inhaled Ceria is deposited in the lung and 
cleared with a half-time of 40 days; at aerosol concentra-
tions higher than 0.5 mg/m3, this clearance was impaired 
resulting in a half-time above 200 days (25 mg/m3). After 
5 days, Ceria (>0.5 mg/m3) induced an early inflamma-
tory reaction by increases of neutrophils in the lung which 
decreased with time, with sustained exposure, and also after 
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OPN  Osteopontin
PMN  Polymorphnuclear neutrophil
PSF  Phagolysosomal simulant fluid
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Introduction
During the production and processing of nanomaterials in 
the workplace, releases into the air may occur (Kuhlbusch 
et al. 2011). Therefore, inhalation is considered to be the 
major route of concern. Furthermore, pulmonary inflamma-
tion, fibrosis, and lung cancer are most important adverse 
effects after chronic inhalation exposure of rats to poorly 
soluble, non-fibrous (nano)particles of low toxicity (PSP) 
(Oberdorster 2002). Tumor formation in rat lungs after 
long-term PSP exposure is thought to be caused by altered 
particle clearance kinetics involving chronic inflammation 
associated with oxidative stress, secondary genotoxicity, 
and cell proliferation (Greim and Ziegler-Skylakakis 2007; 
ILSI Risk Science Institute Workshop Participants 2000). 
A previous study observed that excessive amounts of the 
microscale Titania induced lung tumors in rats after 2-year 
inhalation exposure to a high concentration of 250 mg/m3 
(Lee et al. 1985). Also, nanoscale materials, Titania (P25) 
and carbon black (Printex 90), caused lung tumors in rats 
after 2 years of inhalation to 10 and 11.7 mg/m3, respec-
tively (Heinrich et al. 1995; Nikula et al. 1995). The tumor 
incidence observed in these studies was high (32–29 %). 
Only high concentrations were tested in these studies, and 
no information about detailed deposition, clearance, and 
retention was provided. Thus, the existing studies contrib-
ute little to the understanding of the mechanisms of nan-
oparticle-induced tumor formation by long-term inhala-
tion (Becker et al. 2011). Standardized long-term studies 
according to the test guidelines with a distinct study design 
and concentration selection focusing on exposure dose–
response relationships are crucial for risk assessment and 
derivation of occupational safety values, as well as for clas-
sification and labeling under REACH (Becker et al. 2011; 
European Commission 2013).
Therefore, an appropriate long-term inhalation study has 
been initiated as a collaboration of the German government 
with BASF within the OECD sponsorship programme and 
the EU-project NanoREG (Teunenbroek et al. 2013; Fed-
eral Ministry for the Environment 2012). This study is per-
formed according to OECD test guideline No. 453 (OECD 
2009a). Nano-Ceria was selected as a test material repre-
senting a poorly soluble particle because of its importance 
for industrial applications. Nano-Ceria is used as an UV-
absorbent, a polishing agent for silicon wafers, and a fuel 
additive to decrease diesel particle emission (Cargnello et al. 
2013). The OECD has added Ceria to the list of representa-
tive manufactured nanomaterials for toxicological evalu-
ations (NM-211, NM-212, NM-213) (Demokritou et al. 
2012; OECD 2010). The short-term studies with 5 days 
and 4 weeks of exposure presented in this manuscript pro-
vide information on biokinetics and effects of nano-Ceria 
required for the design of a long-term inhalation study.
Till now, the available knowledge concerning inhalation 
toxicity of Ceria is limited. In an acute study, 4-h nose-
only exposure to 641 mg/m3 nano-Ceria in rats resulted in 
pulmonary inflammation and the formation of multifocal 
microgranulomas in lung after 14 days of post-exposure. 
This was explained by the impaired clearance of the par-
ticles from the lung (Srinivas et al. 2011). In a whole-body 
4-day inhalation study, exposing rats to 2.7 mg/m3 nano-
Ceria 2 h/day, lung injury, and inflammation were observed 
after 1 day post-exposure (Demokritou et al. 2012). 
In a 28-day inhalation study of micro- and nano-Ceria 
(10.79 mg/m3 NM-211, 19.95 mg/m3 NM-212, 55.0 mg/
m3 NM-213) in rats, high lung burdens, distribution of 
inhaled Ceria to various extrapulmonary organs, and slow 
tissue clearance from the lung were observed (Geraets et al. 
2012). Furthermore, 28-day nose-only inhalation of 2 mg/
m3 nano-Ceria in mice induced severe and chronic inflam-
mation including necrosis; proteinosis; fibrosis and granu-
lomas in the lungs; and severe changes in kidney, liver, and 
heart (Aalapati et al. 2014). These strong effects were asso-
ciated with significant accumulation of the nanoparticles in 
the (extra)pulmonary tissues and indicated that inhalation 
of Ceria can lead to pulmonary and extrapulmonary tox-
icity. There were also a few instillation studies assessing 
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toxicity of nano-Ceria (He et al. 2010; Nalabotu et al. 
2011; Ma et al. 2011, 2014; Molina et al. 2014). After sin-
gle intratracheal instillation of 0.15, 0.5, 1.3, 5, and 7 mg/
kg in male Sprague–Dawley rats, Ceria caused concentra-
tion-dependent alveolar macrophage functional change, 
significant lung inflammation, and cytotoxicity, indicating a 
potential shift from a proinflammatory environment to final 
pulmonary fibrosis (Ma et al. 2011). However, instillation 
studies usually have a bolus of high dose and high dose rate 
in the lung and are therefore less suitable to determine the 
exposure concentrations, biokinetics, and biological effects 
toward the design of a long-term inhalation study (Baisch 
et al. 2014). The majority of the published studies indi-
cate an inflammatory potential of Ceria but lack appropri-
ate dose metrics and biokinetic information (Cassee et al. 
2011; Becker et al. 2011).
The short-term studies with 5 days and 4 weeks of expo-
sure described in this manuscript provide data on bioki-
netics as well as pulmonary and potential extrapulmonary 
effects of two nano-Ceria (NM-211 and NM-212) using 
established and standardized study protocols. Whole-body 
exposure is the only option for exposure routes in long-
term studies for animal welfare reasons because the ani-
mals are not restrained during the exposure. Furthermore, 
oral and dermal uptake of different micro- and nano-sized 
test materials has been proven to be negligible (Landsiedel 
et al. 2012; Gamer et al. 2006; Pflucker et al. 2001; Molina 
et al. 2014).
Physicochemical properties of nanoparticles can have 
a significant influence on their fate and biological effects 
(Oberdorster et al. 1994a; Anjilvel and Asgharian 1995). 
Therefore, the two nanoparticles were characterized in 
accordance with the nano-specific guidance in REACH, as 
validated earlier with other materials from the OECD spon-
sorship programme (Wohlleben et al. 2013). Persistence 
and solubility in different media were investigated to study 
the bioavailability of the tested Ceria. Comprehensive 
characterizations of the test atmospheres were performed 
according to the respective guidelines and OECD guidance 
documents (ECHA 2012; Hussain et al. 2009).
Materials and methods
General
Two short-term studies (5 days and 4 weeks of exposure) 
were designed using two different nano-Ceria. In the short-
term study with 5 days of exposure, we compared two 
Ceria (NM-212 and NM-211) with regard to their inha-
lation toxicity, deposition, and clearance kinetics. Ceria 
(NM-212) was tested further after 4 weeks of exposure. 
In order to compare the effects after different exposure 
durations, same target concentrations were selected for the 
two studies. Biological effects of Ceria were studied by 
the analysis of bronchoalveolar lavage fluid (BALF) and 
blood and histopathology of the respiratory tract. Biokinet-
ics were assessed by the determination of lung and lung-
associated lymph node burdens at different time points. The 
short-term inhalation studies were performed according to 
the OECD Principles of Good Laboratory Practice (GLP) 
[Organization for Economic Cooperation and Development 
(OECD) 1998]. The study design of the study with 4 weeks 
of exposure was carried out according to the OECD guide-
lines for testing of chemicals, Section 4: Health Effects, 
No. 412, with additional modifications [Organization for 
Economic Cooperation and Development (OECD) 2009b]. 
To increase the comparability, the short-term studies were 
performed in the same inhalation laboratory under the same 
test conditions, determining same end points for assessing 
biological effects and deposition and clearance kinetics. 
This facilitated a direct comparison between the measured 
parameters.
Test materials and characterization
The two Ceria test materials in this work are NM-211 and 
NM-212 received from the OECD sponsorship programme 
for safety testing of manufactured nanomaterials (Hussain 
et al. 2009). Very recently, the European Chemicals Agency 
(ECHA) drafted a nano-specific guidance document, des-
ignated as Appendix R7-1 (Hermans 1963). The following 
end points for the characterization of the aerosol materials 
were considered as follows: agglomeration/aggregation, 
particle size distribution, water solubility/dispersability, 
crystalline phase and size, representative electron micros-
copy (TEM) for morphology, specific surface area, zeta-
potential (surface charge), surface chemistry, photocatalytic 
activity, purity and impurities, and porosity. The methods 
to characterize these properties are described in detail in 
a previous work (Wohlleben et al. 2013). The agglomer-
ate density of Ceria NM-212 was derived from mercury 
porosimetry (see Fig. S1). By integrating all void volumes 
up to the agglomerate outer dimensions of 1.1 µm, the 
agglomerate density of NM-212 would be 2.0 g/m3 based 
on the mercury porosimetry measurement. The density of 
NM-211 was determined consistently. The agglomerate 
density was used in the calculation of expected lung burden 
by multiple-path particle dosimetry (MPPD) model (Anjil-
vel and Asgharian 1995).
Animals
This study was approved by the local authorizing agency 
for animal experiments (Landesuntersuchungsamt Kob-
lenz, Germany) as referenced by the approval number G 
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12-3-028. Animals were housed in an AAALAC-accredited 
facility in accordance with the German Animal Welfare 
Act and the effective European Council Directive. Female 
Wistar rats [strain: Crl:WI(Han)] were obtained at an age 
of 7 weeks from Charles River Laboratories (Sulzfeld, Ger-
many). The animals were maintained in groups up to five 
animals in a polysulfone cage [H-Temp (PSU)], TECNI-
PLAST, Germany) with a floor area of about 2,065 cm2 
(610 × 435 × 215 mm) with access to wooden gnawing 
blocks, GLP-certified feed (Kliba laboratory diet, Provimi 
Kliba SA, Kaiseraugst, Basel Switzerland), and water ad 
libitum. Animal room was kept at 20–24 °C and relative 
humidity 30–70 % with 15 air changes/h. A light/dark cycle 
of 12 h each was kept throughout the study periods. To 
adapt to the exposure conditions, the animals were acclima-
tized to fresh air under the study flow conditions in whole-
body inhalation chambers for 2 days before the start of the 
exposure period. Up to 2 animals/cage were exposed in 
wire cages, type DKIII (BECKER & Co., Castrop-Rauxel, 
Germany) in a whole-body chamber. During the exposure, 
feed and drinking water were withdrawn from the animals.
Inhalation system
The animals were exposed in wire cages that were located 
in a stainless steel whole-body inhalation chamber 
(V = 2.8 m3 or V = 1.4 m3). The inhalation atmospheres 
were passed into the inhalation chambers with the supply 
air and were removed by an exhaust air system with 20 air 
changes/h. For the control animals, the exhaust air system 
was adjusted in such a way that the amount of exhaust air 
was lower than the filtered clean, supply air (positive pres-
sure) to ensure that no laboratory room air reaches the con-
trol animals. For the treated animals, the amount of exhaust 
air was higher than the supply air (negative pressure) to 
prevent the contamination of the laboratory as a result of 
potential leakages from the inhalation chambers.
Aerosol generation and monitoring
Ceria aerosols were produced by dry dispersion of powder 
pellets with a brush dust generator (developed by the Tech-
nical University of Karlsruhe in cooperation with BASF, 
Germany) using compressed air (1.5 m3/h). The so gener-
ated dust aerosol was diluted by conditioned air (54.5 m3/h) 
passed into whole-body inhalation chambers. The control 
group was exposed to conditioned, clean air. The desired 
concentrations were achieved by varying the feeding speed 
of the substance pellet and by varying the rotating speed of 
the brush. Based on the data of a comprehensive technical 
trial, the aerosol concentrations within the chambers were 
considered to be homogenous (data not shown). Neverthe-
less, the positions of the exposure cages were rotated within 
each chamber. Generated aerosols were continuously moni-
tored by scattered light photometers (VisGuard, Sigrist). 
Particle concentrations in the inhalation atmospheres were 
analyzed by gravimetric measurement of air filter samples. 
Particle size distribution was determined gravimetrically by 
cascade impactor analysis using eight stages Marple per-
sonal cascade impactor (Sierra Anderson, USA). In addi-
tion, light-scattering aerosol spectrometer (WELAS® 2000, 
Palas, Karlsruhe, Germany) was used to measure particles 
from 0.24 to 10 µm. To measure particles in the submi-
crometer range, scanning mobility particle sizer (SMPS 
5.400, Grimm Aerosoltechnik, Ainring, Germany) was 
used. The sampling procedures and measurements to char-
acterize the generated aerosols were described in detail in a 
previous work (Ma-Hock et al. 2007).
Study design of short-term studies (5 days and 4 weeks 
of exposure)
In general, the animals were whole-body exposed to dust 
aerosols for 6 h/day on 5 consecutive days/week with a 
respective post-exposure period (see Fig. 1). The highest 
aerosol concentration was 25 mg/m3, which was expected 
to cause biological effects and should lead to lung over-
load at least for 20 exposures. The mid and low aerosol 
concentrations were 5 and 0.5 mg/m3. The low aerosol 
concentration with an expected lung burden far below the 
overload condition should not lead to any adverse effects. 
The mid aerosol concentration, which was spaced tenfold 
higher than the low concentration, was expected to cause 
some biological effects. The post-exposure period and 
the examination time points were scheduled to address 
the progression or regression of the biological effects, 
with their correlation to lung burden and lung clearance 
kinetics.
Clinical examinations
Clinical observations of the animals were recorded for 
each animal at least three times per day on exposure days 
and once a day during the pre-exposure and post-exposure 
periods. Signs and findings were recorded for each ani-
mal. During exposure, examination was possible only on 
a group basis. The animals were weighed prior to the pre-
exposure period, at the start of the exposure period (day 0), 
and twice weekly until killing or twice within the 5 expo-
sure days.
Hematology and clinical chemistry
Blood sampling of five fasted rats per test group was per-
formed in the morning by retro-orbital venous plexus punc-
ture under isoflurane anesthesia (Isoba®, Essex GmbH 
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Munich, Germany). The extent of the examination was 
according to the data requirements of OECD test guideline 
412. The parameters such as red blood cell counts, hemo-
globin, hematocrit, mean corpuscular volume (MCV), 
mean corpuscular hemoglobin content (MCH), mean cor-
puscular hemoglobin concentration (MCHC), platelet 
counts, total white blood cell as well as differential blood 
cell counts were determined in the EDTA-stabilized blood 
with a hematology analyzer (ADVIA® 120, Siemens Diag-
nostics, Fernwald, Germany). Additionally, acute-phase 
proteins were determined in serum: rat haptoglobin and 
rat γ2-macroglobulin (ELISA by Immunology Consultants 
Laboratory Inc., Newberg, OR, USA) were measured with 
a Sunrise MTP Reader (Tecan AG, Switzerland) by using 
the Magellan Software provided by the instrument pro-
ducer. The enzyme levels [alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), alkaline phosphatase 
(ALP), γ-glutamyltransferase (GGT)] and different blood 
parameters of clinical chemistry were evaluated by using 
an automatic analyzer (Hitachi 917; Roche, Mannheim, 
Germany).
Systemic genotoxicity (micronucleus test)
Systemic genotoxicity (micronucleus test) was performed 
in the short-term studies with 5 days and 4 weeks of expo-
sure (3 and 2 days after the end of exposure, respectively). 
Micronucleus analysis in erythrocytes of rat peripheral 
blood was performed with the MicroFlow® plus (Rat 
Blood) kit from Litron Laboratories, Rochester, NY, USA. 
The flow cytometric differentiation of reticulocytes as well 
as normochromic erythrocytes with and without micronu-
clei was done on the FacsCalibur instrument (BectonDick-
inson, Heidelberg, Germany) after staining of the cells with 
CD71 and propidium iodide.
Bronchoalveolar lavage
Five animals per test group were killed by exsanguina-
tion from the aorta abdominals and vena cava under 
pentobarbital (Narcoren®) anesthesia. The lungs of the 
animals were lavaged in situ twice with 6 mL (22 mL/
kg body weight) of 9 % (w/v) saline solution. A total of 
11 mL BALF was obtained per animal for analysis. Ali-
quots of the BALF were used for the determinations of 
total protein concentration, total cell count, differen-
tial cell count, and activity of the enzymes. In the short-
term study with 5 days of exposure, BALF was analyzed 
3 and 24 days after the end of exposure. After 4 weeks 
of exposure, lavaged lungs and aliquots of the BALF 
(1 mL) were stored at −80 °C and used for the deter-
mination of the Cer content in the lung (lung burden) 1 
and 35 days after the end of exposure. Total BALF cell 
counts were determined with an ADVIA® 120 (Siemens 
Diagnostics, Fernwald, Germany) hematology analyzer. 
Counts of macrophages, polymorphonuclear neutrophils 
(PMN), lymphocytes, eosinophils, monocytes, and atypi-
cal cells were performed on Wright-stained cytocentri-
fuge slide preparations (Warheit and Hartsky 1993). The 
differential cell count was evaluated manually by count-
ing at least 400 BALF cells per sample. Using a Hitachi 
917 (Roche Diagnostics, Mannheim, Germany) reaction 
rate analyzer, levels of BALF total protein and activities 
of lactate dehydrogenase (LDH), alkaline phosphatase 
(ALP), γ-glutamyltransferase (GGT), and N-acetyl-β-
glucosaminidase (NAG) were measured.
Cytokines and chemokines (in BALF and serum)
Cytokines and chemokines in BALF and serum were meas-
ured at Rules-based Medicine Inc., Austin, TX, USA, with 
xMAP technology (Luminex Corp., Austin, TX, USA). 
The measured parameters comprised various cytokines, 
chemokines, adhesion molecules, matrix metalloprotein-
ases, acute-phase proteins, signal proteins of apoptosis, or 
cell proliferation. Briefly, a list of parameters was described 
previously (Ma-Hock et al. 2009). After evaluation of the 
most sensitive parameters or reaction patterns in previous 
studies, the following standard parameters were chosen for 
characterizing the lung inflammation in BALF:
Fig. 1  Study design of short-
term studies with 5 days and 
4 weeks of exposure
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•	 Rat monocyte chemoattractant protein-1 level (rat 
MCP-1; Instant ELISA, Bender MedSystems, Vienna, 
Austria (cat. no BMS631INST);
•	 Rat cytokine-induced polymorphonuclear neutrophil 
chemoattractant-1 level (rat CINC-1/IL-8; ELISA, R&D 
Systems Inc., Minneapolis, USA (Quantikine rat CINC-
1, cat. no. RCN100);
•	 Macrophage colony-stimulating factor (M-CSF; Quan-
tikine Mouse M-CSF ELISA, R&D Systems Inc., Min-
neapolis, USA (cat no. MMC00);
•	 Rodent osteopontin; ELISA, R&D Systems, Inc., Min-
neapolis, US (Quantikine mouse osteopontin, cat. no. 
MOST00).
•	 The cell mediators were measured at a sunrise MTP 
reader (Tecan AG, Switzerland) by using the Magellan 
Software provided by the instrument producer. Four 
chemokines and cytokines were measured using ELISA 
test kits: MCP-1, IL-8/CINC-1, M-CSF, and osteopon-
tin. The detailed procedure was described previously 
(Ma-Hock et al. 2009).
Pathology
In the short-term studies, necropsy and histopathology 
were performed after 5 days of exposure and 21 days after 
the end of exposure (5 days of exposure) and 2 and 34 days 
after the end of exposure (4 weeks of exposure). In general, 
five animals per test group were investigated for pathologi-
cal examination in both short-term studies. For the short-
term study with 4 weeks of exposure, however, ten animals 
were examined for pathological examination of the respira-
tory tract and all gross lesions. At necropsy, animals were 
exsanguinated by opening of the abdominal great vessels 
under deep pentobarbital anesthesia. All organs were pre-
served according to OECD TG No. 412. Following organs 
were weighed: adrenal glands, brain, heart, ovaries, uterus 
with cervix, kidney, liver, lungs, spleen, thymus, and thy-
roid glands. The lungs were instilled (30 cm water column) 
with and fixed in 10 % neutral-buffered formalin (NBF). 
After 24- to 48-h fixation in 10 % NBF, the lungs were 
transferred to 70 % ethanol. All other organs were fixed 
in 10 % NBF. All the organs and tissues described in the 
OECD TG No. 412 were trimmed according to the RITA 
trimming guides for inhalation studies (Kittel et al. 2004; 
Ruehl-Fehlert et al. 2003). After paraplast-embedding, the 
blocks were cut at 2- to 3-µm thickness, mounted on glass 
slides and stained with hematoxylin and eosin. Extrapul-
monary organs and the respiratory tract compromising 
nasal cavity (four levels), larynx (three levels), trachea 
(transverse and longitudinal with carina), lung (five lobes), 
and mediastinal and tracheobronchial lymph nodes were 
assessed by light microscopy. For the lungs, whole histo-
pathological examination was performed in animals of all 
test groups. For all other tissues, only the animals of the 
control and high concentration group of Ceria were ini-
tially examined. When changes were observed in the high 
concentration group, respective organs and tissues of the 
animals exposed to low and intermediate aerosol concen-
trations were also examined by light microscopy. All his-
topathological examinations were performed by a well-
experienced board-certified veterinarian toxicopathologist 
followed by an internal pathology peer review.
Organ burden analysis
Lung burden of the two different Ceria was evaluated 
twice, immediately after 5 days of exposure and after 
21 days after the exposure end. In the short-term study with 
4 weeks of exposure, Cerium content was determined at 
seven time points over 129 days of post-exposure period. 
Cerium content in the lungs, lung-associated lymph nodes, 
and liver of either three or five animals per test group were 
examined. 1 and 35 days after the end of exposure (4 weeks 
of exposure), the lavaged lungs and aliquots of BALF of 
five animals per group were used for the determination of 
lung burden. This examination method has likely caused a 
loss of the test material during preparation and handling of 
the lungs. Furthermore, lung burdens were measured 2 days 
after the end of exposure using the left half lungs of five 
animals/test group, only. On the basis of the availability of 
total lung weights, lung burdens were calculated up from 
the half lung burden values with the corresponding weight 
of the half lungs. Lung burden of the remaining time points 
was determined using the whole (not lavaged) lung. After 
digestion with mixed acid, samples of each lung or lymph 
node were dissolved in sulfuric acid and ammonium sul-
fate. 140Cer content in the obtained solution was analyzed 
by inductively coupled plasma mass spectrometry (ICP-
MS, Agilent 7500 C) or by inductively coupled plasma 
optical emission spectrometry (ICP-OES, Varian 720-ES) 
with a wavelength of 419 nm. With this method, limit of 
detection for Cer is 0.3 μg. The amounts of Ceria in the 
respective tissues were calculated by measuring elemental 
Cerium with ICP-MS.
Statistical analysis
For body weight changes, Dunnett’s test was used for a 
comparison of each test group with the control group test 
(Dunnett 1955; Dudewicz et al. 1975). Clinical pathology 
parameters (BALF cytology, enzyme data, and BALF and 
serum cell mediator data) were analyzed by nonparamet-
ric one-way analysis using the Kruskal–Wallis test (two-
sided). If the resulting p value was ≤0.05, a pair-wise 
comparison of each test group with the control group was 
performed using the Wilcoxon test or the Mann–Whitney U 
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test (both two-sided) (p ≤ 0.05 for statistical significance). 
Comparison of organ weights among test groups was per-
formed by nonparametric one-way analysis using the two-
sided Kruskal–Wallis test, followed by a two-sided Wil-
coxon test for the hypothesis of equal medians in case of 
p ≤ 0.05.
Results
Characterization of test material
Both Ceria were yellowish white powders that were pro-
duced by precipitation and were nominally uncoated. 
We completely re-characterized the Ceria NM-211 and 
NM-212 based on the nano-specific guidance on physical–
chemical properties (Wohlleben et al. 2013). Table 1 indi-
cates the techniques chosen for each end point (see “Mate-
rials and methods” section) and summarizes the results. 
The Ceria NM-212 material had an average primary parti-
cle diameter of 40 nm, in excellent accordance of electron 
microscopy with the crystallite size derived from the dif-
fraction peak width and with the sphere-equivalent diam-
eter derived from the BET-specific surface area of 27 m2/g 
(see Fig. 2). The Ceria NM-211 material consisted of con-
siderably smaller primary particles with number-based 
median diameter of 8.2 nm (from TEM) and correspond-
ingly larger specific surface (53 m2/g, from BET). Primary 
particles of both materials were crystalline with cubic lat-
tice as it is the characteristic for cerianite and had irregular, 
but roughly globular shapes. In the as-produced powder, 
porosimetry by Hg intrusion indicated that these particles 
were aggregated and agglomerated to sizes that range from 
a few hundred nm to tens of µm.
The surface of Ceria NM-212 beared organic contami-
nations. An assessment by thermogravimetry (TGA) con-
firmed that the total organic content remained below 0.7 %, 
but the photoelectron signal of XPS, which had an infor-
mation depth between 3 and 10 nm, indicated 80 % carbon 
atoms on the surface. The contamination was hence a very 
thin and homogeneous layer around the purely inorganic 
particles. According to the fit of photoelectron energies 
from C(1s) level and from O(1s) level, the contamination 
could be an ester with a long alkyl chain. In contrast, the 
Ceria NM-211 had only 14 % carbon atoms on the surface 
(by XPS), and the even more sensitive SIMS techniques 
confirmed that Ceria dominated the surface, with vanish-
ing amounts of nitrates and alkyls. The Cerium atoms at 
crystalline edges were known to be redox-active, which 
was confirmed by the detection of 14 % of the Cerium as 
Ce(III) (within the XPS-accessible surface layer) in Ceria 
NM-212, respectively, 22 % for the Ceria NM-211 with its 
decreased radius of curvature.
If dispersed in clean water, the Ceria NM-212 surface 
was positively charged across the entire physiological pH 
range, with a zeta-potential of +42 mV at pH 7. The sur-
face of Ceria NM-212 was rather reactive in a photocata-
lytic assay with a photon efficiency of 1.3 × 10−2, which 
was 5 times higher than the well-known Titania P25 (NM-
105) and an order of magnitude higher than for the Ceria 
NM-211, leaving the possibility of the organic contamina-
tions being responsible for that catalytic activity, observed 
only under UV irradiation (Wohlleben et al. 2013; Molina 
et al. 2014). After dispersion in water by stirring only, the 
dispersability was limited with average agglomeration 
numbers (AAN = the ratio of agglomerate diameter to pri-
mary particle diameter) above 10, based on the measure-
ment of the resulting agglomerates that were just below the 
micron range (by analytical ultracentrifugation), and tended 
to be larger for the Ceria NM-211 than for NM-212, con-
firming earlier findings of the PROSPECT consortium and 
the European Commission’s JRC report (Hermans 1963; 
PROSPEcT: Ecotoxicology Test Protocols for Representa-
tive Nanomaterials in Support of the OECDSponsorship 
Programme 10 A.D.; European Commission 2014).
The solubility in physiological media was investigated 
by 28-day abiotic incubation in different fluids and detec-
tion of both the remaining particulate fraction (by SEM, 
centrifugation, LD, zeta-potential) and of the released 
metal ions (by ICP-MS). Both Ceria were insoluble except 
for marginal solubility in 0.1 N HCl (simulate oral inges-
tion), whereas a nanoscale precipitated Silica as positive 
control dissolved readily and Titania (NM-105) showed 
marginal solubility in phagolysosomal simulant fluid (PSF, 
simulate uptake and digestion in macrophages) (Wohlle-
ben et al. 2013). In buffers with organic constituents (PSF, 
fasted state simulated intestinal fluid = FaSSIF), the sur-
face charge reversed to negative zeta-potentials, which 
was identified earlier as indicator for the adsorption of 
constituents of the buffer for a range of the nano-Ceria 
(Wohlleben et al. 2013). Under all conditions, primary par-
ticles remained recognizable in TEM scans, but both Ceria 
NM-211 and NM-212 formed large structures after 28-day 
incubation in the acidic PSF medium that simulates the lys-
osome of macrophages (see Fig. 3). We found by selected 
area electron diffraction (SAD) that these aged structures 
retained the same cubic cerianite crystalline phase of the 
as-produced powder for both Ceria NM-211 and NM-212. 
Under identical conditions, also other nanomaterials, e.g., 
the Titania (NM-105), aged into similar structures, and 
we added the respective TEM and SAD for comparison 
(Wohlleben et al. 2013).
To summarize the comparative physical–chemical 
characterization, Ceria NM-211 and NM-212 had identi-
cal composition, agglomeration state, crystallinity, and 
insolubility. Compared to NM-212, the Ceria NM-211 
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had considerably smaller primary particles, larger specific 
surface, significantly fewer organic contaminations on the 
surface, and much reduced photocatalytic activity. Despite 
these differences, Ceria NM-211 and NM-212 shared the 
same tendency to recrystallize in PSF.
Characterization of test atmosphere
The target concentrations were 0.5, 5, and 25 mg/m3 in the 
short-term studies (5 days and 4 weeks of exposure) with 
nano-Ceria NM-212. In the study with 5 days of exposure, 
Fig. 2  Structure of Ceria. 
Electron microscopy images 
of a representative ensemble of 
particles of Ceria NM-211 (a) 
and NM-212 (b) (see Table 1 
for size characterization by 
complementary methods)
Fig. 3  Persistence of Ceria NM-211 (a), NM-212 (b), and Titania 
NM-105 (c) as benchmark. Transmission electron microscopy (TEM) 
and selected area diffraction (SAD) after 28-day incubation in phago-
lysosomal simulant fluid (PSF) [see Table 1 for dissolution detected 
by ions in the supernatant (ICP-MS)]. The large almost spherical 
structures are no contaminations, but are confirmed as Ceria in the 
same crystalline phase
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0.5 and 25 mg/m3 were selected for nano-Ceria NM-211. 
Analyzed concentrations and particle size distributions are 
summarized in Table 2. The target concentrations were met 
and maintained well throughout the studies. Particle size 
distribution demonstrated that Ceria particles were in the 
respirable range for rats.
Clinical examination
Five days and 4 weeks of inhalation exposure to Ceria 
NM-212 and NM-211 did not affect the body weight devel-
opment of the animals (data not shown). The animals exposed 
to Ceria NM-211 and NM-212 showed no clinical signs or 
findings compared to the control animals (data not shown).
Hematology, clinical chemistry, cytokines, and chemokines 
in serum
Five days of exposure
Absolute and relative neutrophil counts in blood were 
increased 3 days after the end of exposure to 25 mg/m3 
Ceria NM-212 and NM-211, whereas relative lymphocyte 
counts were decreased (see Table S2). The changes were 
in a concentration-related manner. 24 days after the end of 
exposure, all parameters had returned to near control val-
ues. No other blood parameters were affected.
Four weeks of exposure
Hematological, clinical chemistry parameters, and acute-
phase protein levels were not affected in rats exposed to 
Ceria NM-212 (see Table S2; the other data are not shown).
Systemic genotoxicity (micronucleus test)
Micronuclei in the erythrocytes of peripheral blood cells 
were counted to assess chromosomal aberrations of 
hematopoietic cells in the bone marrow. Peripheral blood 
cells were examined in the short-term studies with 5 days 
and 4 weeks of exposure (3 and 2 days after the end of 
exposure, respectively). All examined parameters were in 
the range of control values (see Table S3).
Bronchoalveolar lavage (BAL)
In the short-term studies with 5 days and 4 weeks of expo-
sure, BALF analysis of five animals per test group was 
obtained 3 days or 1 day after the end of exposure and 24 or 
35 days after the end of exposure, respectively (see Fig. 1). 
The resulting BALF parameters are presented in Table 3.
Five days of exposure
In animals exposed to Ceria NM-212, the majority of 
BALF parameters were increased at aerosol concentra-
tions of 5 mg/m3. At 0.5 mg/m3, the neutrophil counts and 
cytokine-induced neutrophil chemoattractant-1 (CINC-1) 
were both statistically increased and were slightly above 
the historical control range (see Table S4). With Ceria 
NM-211, but not NM-212, monocyte chemoattractant pro-
tein-1 (MCP-1) and macrophage colony-stimulating fac-
tor (M-CSF) were increased at aerosol concentrations of 
0.5 mg/m3 and above. 24 days after the end of exposure, 
a full recovery was observed at aerosol concentrations of 
0.5 mg/m3 and a partial recovery at aerosol concentrations 
of 5 and 25 mg/m3. The recovery of animals exposed to 
25 mg/m3 Ceria NM-211 seems to be slower than those 
exposed to NM-212.
4 weeks of exposure
Four weeks of inhalation exposure to 5 and 25 mg/m3 Ceria 
NM-212 resulted in an increase in total cells in BALF due 
to increases in polymorph nuclear neutrophils, lympho-
cytes, and monocytes in BALF (see Table 3). Consistent 
Table 2  Measured concentrations and particle size distributions of Ceria







mean ± SD (mg/m3)
MMAD (µm)/ 
GSD mean
Particle count  




5 days of 
exposure
Ceria NM-212 0.5 0.5 ± 0.2 1.4/2.3 2,583 283
5 5.3 ± 0.9 1.2/2.1 137,096 206
25 25.9 ± 6.0 1.0/2.5 537,548 171
Ceria NM-211 0.5 0.48 ± 0.0 1.6/2.1 5,689 256
25 5.2 ± 1.1 1.3/2.1 84,655 167
4 weeks of 
exposure
Ceria NM-212 0.5 25.6 ± 6.0 0.9/2.5 514,193 203
5 0.45 ± 0.1 1.9/2.9 1,503 242
25 25.8 ± 1.7 2.2/2.4 160,162 188






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2045Arch Toxicol (2014) 88:2033–2059 
1 3
with these findings, several other parameters including the 
examined cell mediators were increased. 35 days after the 
end of exposure, some of the BALF parameters returned to 
control levels, whereas several of them were still signifi-
cantly increased at 5 and 25 mg/m3 (e.g., total cells, lym-
phocytes, neutrophils; GGT, LDH, ALP; MCP-1, CINC-1).
Five days of exposure caused slightly higher neutrophil 
and lymphocyte counts at aerosol concentrations of 25 mg/
m3 Ceria NM-212 compared to 4 weeks of exposure (see 
Fig. 4). CINC-1 was already increased at 0.5 mg/m3 after 
5 days but not after 4 weeks of exposure. The regression 
of the BALF parameters was faster after 5 days than after 
4 weeks of inhalation exposure. Cell mediators, especially 
MCP-1, were higher elevated at concentrations of 5 and 
25 mg/m3 after 4 weeks than after 5 days of exposure.
Pathology
Organ weights and macroscopic findings
Five days of exposure After 5 days of exposure, no 
increase in lung weights was observed after exposure to 
Ceria NM-212 (see Table S5). An aerosol concentration of 
25 mg/m3 Ceria NM-211, however, resulted in significant 
increases in absolute and relative lung weights (+20 and 
24 %, respectively, p < 0.01). The increase in lung weight 
was no longer present 21 days after the end of exposure. 
After 5 days of exposure, the macroscopic finding enlarged 
mediastinal lymph nodes were found in individual animals 
of all test groups (see Table S5). 21 days after the end 
of the exposure, enlarged mediastinal lymph nodes were 
observed in almost all animals exposed to Ceria NM-211 
or NM-212. The tracheobronchial lymph nodes and all 
other examined organs did not show any macroscopic 
findings.
Four weeks of exposure Absolute and relative lung 
weights were significantly increased at aerosol concentra-
tions of 25 mg/m3 Ceria NM-212 (+30 and 29 %, respec-
tively) 2 days after the end of the exposure and were still 
significantly elevated (+16 and 20 %) 34 days after the 
end of the exposure (see SI, S5). 2 days after the end of 
the exposure, absolute and relative lung weights of ani-
mals exposed to 5 mg/m3 were increased significantly by 
+13 and 10 %, respectively. They returned to control levels 
within the following 34 days. No effects on organ weights 
were observed after inhalation of 0.5 mg/m3. 2 days after 
the end of exposure, mediastinal lymph nodes of two ani-
mals (out of ten) were enlarged at aerosol concentrations 
of 25 mg/m3 Ceria NM-212. 34 days after the end of 
exposure, the incidence of animals with enlarged, yellow 
white-colored mediastinal lymph nodes increased consid-
erably from two to eight (out of ten) per group at aerosol 
concentrations of 25 mg/m3 Ceria NM-212, respectively. 
Mediastinal lymph nodes of animals exposed to 5 mg/m3 
were firstly enlarged 34 days after the end of exposure.
All other extrapulmonary organs including the tracheo-
bronchial lymph nodes revealed no macroscopical findings 
after inhalation exposure to Ceria.
Histopathology
Overall, histopathological evaluations were consistent in 
the short-term studies with 5 days and 4 weeks of exposure. 
The findings assessed in the short-term study with 5 days 
showed lower severities (see Table 4; Fig. 5a–c). 
Lungs
Five days of exposure
After 5 days of exposure, single or accumulated mac-
rophages were located in the lumen of the alveoli and a 
few macrophages occurred also in the alveolar wall and 
ducts. They were distributed multifocally in all lobes over 
the whole lung. Most of them were loaded with amber-like 
colored particles of different sizes (below 1 µm diameter). 
These particles were considered to represent agglomer-
ated or aggregated Ceria particles (“alveolar histiocytosis 
with particles”). Alveolar histiocytosis and free eosino-
philic granular material with particles, interpreted as rem-
nants of destroyed macrophages, were found in the lung 
of almost all animals exposed to 25 mg/m3 Ceria NM-211 
and NM-212. At aerosol concentrations of 0.5 mg/m3 Ceria 
NM-211, 0.5 and 5 mg/m3 Ceria NM-212, amber-colored 
particles were noted within single histiocyte in the alveoli. 
In the bronchus-associated lymphoid tissue (BALT), parti-
cles were detected free or in single macrophages, mostly 
at 5 mg/m3 Ceria and above. Findings regressed but were 
still present 21 days after the end of exposure. The find-
ing “eosinophilic granular material with particles” was no 
longer visible after the post-exposure period. Particles were 
detected free or in single macrophages in BALT, even at the 
lowest concentration of 0.5 mg/m3 Ceria NM-211. Only 
one animal exposed to 25 mg/m3 Ceria NM-211 showed 
macrophage aggregates in BALT 21 days after the end of 
exposure.
Four weeks of exposure
Two days after the end of the exposure, a concentration-
related increase in alveolar macrophages was observed in 
the lungs in all Ceria NM-212-exposed animals (Table 4; 
Fig. 5a). Eosinophilic granular material and small parti-
cles were distributed in the alveoli of animals exposed to 
5 and 25 mg/m3 Ceria NM-212. The occurrence of alveo-
lar histiocytosis and of eosinophilic granular material was 
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correlated with increased lung weights in animals exposed 
to 5 and 25 mg/m3 Ceria NM-212. In BALT, single, small 
macrophage aggregates with particles occurred in ani-
mals exposed to 25 mg/m3 (see Fig. 5b). In addition, sin-
gle or a few amber-like colored particles occurred extra-
cellularly in BALT without any macrophage activation at 
aerosol concentrations of 5 and 25 mg/m3. 34 days after 
the end of exposure, alveolar histiocytosis and eosino-
philic granular material with particles were still observed 
at concentrations of 5 and 25 mg/m3 Ceria NM-212. At 
0.5 mg/m3, in contrast, amber-like colored particles could 
only be noted within single histiocyte. In one animal of 
5 mg/m3 and in five out of ten animals exposed to 25 mg/
m3 Ceria NM-212, a multifocal granulomatous inflamma-
tion appeared first. In BALT, single or few amber-colored 
particles at 0.5, 5, and 25 mg/m3 Ceria NM-212 as well as 
an increasing number of animals with macrophage aggre-
gates with particles at 5 and 25 mg/m3 were still observed 
Fig. 4  Comparison of changes in BALF parameters after 5 days (a, 
b) and 4 weeks (c, d) of exposure to Ceria NM-211 and NM-212: 
short-term study with 5 days of exposure: a 3 days after the end of 
exposure, b 24 days after the end of exposure; short-term study with 
4 weeks of exposure, c 1 day after the end of exposure, d 35 days 
after the end of exposure. Changes are shown as x-fold differences 
compared to controls using a logarithmic scaling
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Table 4  Histopathology of short-term studies with 5 days and 4 weeks of exposure
Target conc. (mg/m3) 5 days of exposure to Ceria NM-212 5 days of exposure to 
Ceria NM-211
4 weeks of exposure to Ceria 
NM-212




Time point 1a Time point 2b
0.5 5 25 0.5 5 25 0.5 25 0.5 25 0.5 5 25 0.5 5 25
Histopathology
Lungs
Alveolar histiocytosis with particles – – 5 – 3 5 – 5 – 4 10 10 10 – 10 10
 Grade 1 1 3 5 3 4 10 4 3
 Grade 2 4 2 6 5 7
 Grade 3 5 10
Eosinophilic granular material/particles – – 5 – – – – 5 – – – 10 10 – 2 10
 Grade 1 2 5 10 2 5
 Grade 2 3 6 4
 Grade 3 4 1
BALT: macrophage aggregates particles – – – – – – – – – 1 – – 5 – 1 8
 Grade 1 1 5 3
 Grade 2 1 2
 Grade 3 3
BALT: occurrence of particles – 2 5 – 3 5 – 5 2 4 – 8 5 3 8 2
Inflammation, granulomatous – – – – – – – – – – – – – – 1 5
 Grade 1 1
 Grade 2 5
Particles within histiocytes 5 5 – 5 2 – 5 – 5 – – – – 10 – –
Mediastinal lymph nodes
Macrophage aggregates particle. – – – – – 4 – – – 2 – – 4 – 9 9
 Grade 1 2 1 2
 Grade 2 1 2
 Grade 3 1 2 6 2
 Grade 4 1 1 7
Occurrence of particles – – 2 – 1 1 – 3 – 2 – 6 6 1 – 1
Hyperplasia, lympho-reticulocellular 1 – 3 – – 3 3 3 – 1 1 1 4 – 2 7
 Grade 1 1 3 2 3 1 1
 Grade 2 1 1 1 1 1 3 2 6
 Grade 3 1 1
Tracheobronchial lymph nodes
Macrophage aggregates particle. – – – – – 4 – – – 3 – 1 8 – 10 10
 Grade 1 1 1 3 1 1
 Grade 2 2 1 5 1 1
 Grade 3 2 5 2
 Grade 4 1 3 6
Occurrence of particles – – 5 – 3 1 – 4 – 2 – 7 2 1 – –
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(see Fig. 5b). All compound-related findings after exposure 
of 5 and 25 mg/m3 Ceria NM-212 were correlated with 
increased lung weights in these test groups.
Lung-associated lymph nodes (mediastinal 
and tracheobronchial lymph nodes)
Five days of exposure
After 5 days of exposure to 25 mg/m3 Ceria NM-211 and 
NM-212, comparable to the finding of particles in BALT 
of the lung, amber-like colored particles were seen partly 
within macrophages or extracellularly in the lymphoid 
tissue, without any macrophage activation or aggrega-
tion. 21 days after the end of exposure to 25 mg/m3 Ceria 
NM-211, findings in both lymph nodes progressed. In the 
mediastinal and the tracheobronchial lymph nodes, mul-
tifocal macrophage aggregates with amber-like colored 
particles were noted in animals exposed to Ceria NM-211 
and NM-212 (see Table 4). In both lymph nodes, lympho-
reticulocellular hyperplasia was observed after 5 days of 
exposure and 21 days after the end of exposure to Ceria 
NM-211 and NM-212.
Four weeks of exposure
Two days after the end of exposure to 5 and 25 mg/m3 Ceria 
NM-212, multifocal macrophage aggregates with particles 
were observed in the mediastinal as well as in the tracheo-
bronchial lymph nodes (see Fig. 5c). A lympho-reticulocel-
lular hyperplasia was present in both lymph nodes, mostly 
seen in animals in the group of 25 mg/m3. The hyperplasia 
of the mediastinal lymph nodes was correlated with their 
corresponding macroscopic enlargement after exposure to 
25 mg/m3 Ceria NM-212. 34 days after the end of expo-
sure, the number of animals with macrophage aggregates 
(incidence and grading) and with hyperplasia in both lymph 
nodes was higher compared to the animals examined 2 days 
after the end of the exposure. Nearly all other findings were 
still present 34 days after the end of the exposure.
Upper respiratory tract
Five days of exposure
After 5 days of exposure to 25 mg/m3 Ceria NM-211 and 
NM-212, extracellular, amber-like colored particles with 
diameters up to 1.5 µm were found in the lamina propria 
mucosae of the dorsal area of the larynx (level III). At 
aerosol concentrations of 25 mg/m3 Ceria NM-211 and 
NM-212, resembling amber-like colored particles were 
detected within the subepithelial tissue in the carina of the 
trachea. 21 days after the end of exposure, findings in the 
larynx were only observed for animals exposed to Ceria 
NM-212, whereas particles in the carina (trachea) were still 
present in animals exposed to Ceria NM-211 and NM-212.
Four weeks of exposure
Two days after the end of the exposure to 5 and 25 mg/
m3 Ceria NM-212, amber-like colored particles occurred 
similarly in the dorsal area of the larynx (level III). Ani-
mals exposed to 25 mg/m3 showed particles in the carina 
of the trachea. At aerosol concentrations of 25 mg/m3 Ceria 
NM-212, single amber-like colored particles were firstly 
found in the nasal-associated lymphoid tissue (NALT), 
inside single macrophages or extracellularly. These find-
ings were still present 34 days after the end of exposure.
Target conc. (mg/m3) 5 days of exposure to Ceria NM-212 5 days of exposure to 
Ceria NM-211
4 weeks of exposure to Ceria 
NM-212




Time point 1a Time point 2b
0.5 5 25 0.5 5 25 0.5 25 0.5 25 0.5 5 25 0.5 5 25
Hyperplasia, lympho-reticulocellular – – 4 1 1 2 – 1 1 1 – 1 7 – 1 6
 Grade 1 4 1 1 2 1 1
 Grade 2 1 1 2 1 1 3 4
 Grade 3 2 1
Number of examined organs per test group: n = 10 (4 weeks of exposure); n = 5 (5 days of exposure)
Grade 1: minimal, grade 2: slight, grade 3: moderate, grade 4: severe, grade 5: extreme; whenever a grading was not used, the microscopic find-
ing was indicated to be present
a
 Time point 1: after the end of exposure (5 days of exposure) and 2 days after the end of exposure (4 weeks of exposure)
b
 Time point 2: 21 days after the end of exposure (5 days of exposure) and 34 days after the end of exposure (4 weeks of exposure)
Table 4  continued
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Extrapulmonary organs
Five days of exposure
Extrapulmonary organs of animals exposed for 5 days to 
Ceria NM-211 and NM-212 were not examined.
Four weeks of exposure
Histological examination of extrapulmonary organs, e.g., 
liver, spleen, and kidneys, did not show any substance-
related morphological changes in animals exposed to 0.5, 
5, and 25 mg/m3 Ceria NM-212 in the short-term study 
with 4 weeks of exposure (data not shown).
Organ burden analysis
In the short-term studies with 5 days and 4 weeks of expo-
sure, Ceria burden of lung, lymph nodes, and partly liver is 
summarized in Tables S6–S8. The time course of lung and 
lymph node burdens is presented in Fig. 6.
Five days of exposure
Exposure to 0.5 mg/m3 Ceria NM-212 resulted in a lung 
burden of 0.011 mg/lung, directly after 5 days of expo-
sure and decreased to 0.006 mg/lung 21 days after the 
end of the exposure, whereas exposure to 5 and 25 mg/
m3 yielded higher lung burdens (0.1 and 0.53 mg/lungs, 
respectively) with only little decrease (0.088 and 0.4 mg/
lung, respectively) within 21 days after the end of the 
exposure.
Lung burdens of Ceria NM-211 were around twofold 
lower compared to those of Ceria NM-212 (see Table S6). 
Cerium content in the lung-associated lymph nodes at 
aerosol concentrations of 25 mg/m3 increased from 1.7 to 
5 µg for Ceria NM-212 and from 1.4 µg to 3 µg for Ceria 
NM-211 in the short-term study with 5 days of exposure 
(see Table S7).
Four weeks of exposure
The time course of the lung burdens is presented in Fig. 6 
(for detailed values, see Table S6). Inhalation exposure of 
0.5, 5, or 25 mg/m3 Ceria NM-212 resulted in mean lung 
burdens of 0.04, 0.52, or 2.62 mg 1 day after the end of 
exposure. 2 days after the end of exposure, higher lung bur-
dens of the left lungs were measured and these data were 
disregarded for half-time calculations. Applying the fol-
lowing equation, retention half-times of Ceria in the lungs 
were calculated as
N(t) = N0 × e−t
where N(t) was the lung burden at time point t, N0 was the 
lung burden shortly after last exposure, t as days after last 
exposure.
At aerosol concentrations of 0.5 mg/m3 Ceria NM-212, a 
retention half-time of 40 days was determined. Higher aer-
osol concentrations of 25 mg/m3 Ceria NM-212 resulted, 
however, in a much longer half-time above 200 days.
The Cerium burden in the lung-associated lymph nodes 
(tracheobronchial and mediastinal lymph nodes) was 10 µg 
3 days after the end of the exposure to 25 mg/m3 Ceria 
NM-212 and increased to 350 µg 129 days after the end of 
exposure (see Table S7).
After the exposure to 25 mg/m3 Ceria NM-212, Cerium 
was also detected in the liver (1.56 and 1.93 µg) 3 and 
65 days after the end of the exposure, respectively (see 
Table S8).
Discussion
Objectives of this body of work were to determine lung 
deposition and clearance kinetics as well as the inhala-
tion toxicity of two nano-Ceria (NM-211 and NM-212) 
in short-term studies with 5 days and 4 weeks of inhala-
tion exposure. The results should serve as basis for select-
ing appropriate exposure concentrations for a subsequent 
long-term inhalation study. The following sections focus on 
a discussion of (1) deposition and clearance, (2) local and 
systemic effects, (3) comparison of the two Ceria NM-211 
and NM-212, and (4) comparison of 5 days and 4 weeks of 
exposure.
Deposition and clearance
Four weeks of exposure to 0.5 mg/m3 Ceria NM-212 
resulted in a lung burden of 41 µg/lung; the post-exposure 
retention half-time was 40 days. This is in the range of 
physiological retention half-times of poorly soluble parti-
cles between 60 and 70 days (Oberdorster 2002). A higher 
aerosol concentration of 25 mg/m3 elicited a lung burden 
of 2,620 µg/lung resulting in a retarded retention half-time 
above 200 days. At the mid concentration of 5 mg/m3, the 
lung burdens at three time points indicated a retarded reten-
tion half-time as the lung burden (500 µg/lung) stayed at 
a constant level during 4 weeks of post-exposure. A pro-
longed lung clearance of the same Ceria NM-212 was also 
observed in a rat instillation study with neutron-activated 
141Ceria NM-212 at an instilled dose of 1 mg/kg body 
weight, corresponding to 200–300 µg/lung (Molina et al. 
2014). During 28 days post-exposure, only 12 % of the 
141Cerium in the lung has been cleared.
Pulmonary inflammation was only observed at concen-
trations of 5 and 25 mg/m3, which also caused significant 
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retardation of pulmonary clearance. Concerning the thresh-
old for overload conditions, mass lung burden of 41 µg, 
achieved at 0.5 mg/m3, was well below the overload 
threshold proposed by Morrow, while the lung burden of 
2,620 µg, achieved at 25 mg/m3, was above it (Morrow 
1988). At 25 mg/m3; a strong pulmonary inflammation was 
apparent. The mid concentration of 5 mg/m3 Ceria NM-212 
elicited pulmonary inflammation at a constant lung burden 
of around 520 µg, which is slightly below or at the border 
of the overload threshold.
Morrow assumed overload conditions when particle 
volume exceeds 60 µm3/alveolar macrophage (Morrow 
1988). Oberdoerster et al. (1994a) suggested retained sur-
face area as appropriate metrics for correlating overload 
with retarded clearance, particularly if nanoparticles are 
involved. Tran et al. (2000) proposed overload thresh-
old values of 0.02–0.03 m2/g lung. In the current study, 
4 weeks of exposure to an aerosol concentration of 25 mg/
m3 caused a particle surface burden of 0.07 m2/lung and 
5 mg/m3 resulted in 0.014 m2 surface burden per lung (see 
Fig. 7; Table S9). This is slightly below the surface bur-
den threshold proposed by Tran et al. and caused already 
inflammation and retarded clearance in the lung. Therefore, 
it can be assumed that a threshold, however, is highly mate-
rial-dependent and may not be based on one or two particle 
types alone. The thresholds published previously may need 
adaptations for the specific type of nanomaterial in order to 
address its toxicological properties.
Lung burdens after 5 days of exposure were about one-
fourth of those after 4 weeks of exposure reflecting a linear 
kinetics. This is the consequence of a linear deposition and 
a slow clearance. In the long term, however, the kinetics 
will not be linear due to clearance.
In the lung-associated lymph nodes, 350 µg Ceria was 
found 129 days after the exposure to 25 mg/m3 for 4 weeks. 
The lung burden decreases from 2,620 to 1,800 µg in the 
same time period. The lymphatic clearance of Ceria was 
around 13 % of the initial retained burden after the end of 
the exposure. Lymphatic clearances of 1–5 % were previ-
ously reported for microscale particles but were also shown 
to be higher for nanoscale particles (Kreyling and Scheuch 
2000; Kreyling et al. 1986; Oberdorster et al. 1994b). 
Most of the Ceria nanoparticles were presumably cleared 
by mucociliary clearance and subsequent fecal excretion, 
which was not evaluated in this work.
A very low content of Ceria was detected in the liver in 
the presented inhalation study with 4 weeks of exposure 
to 25 mg/m3 Ceria NM-212. Consistent with our findings, 
accumulation of Ceria NM-212 in extrapulmonary tissue 
and associated toxicity appeared to be low as reported in 
a rat study using intravenous injection of neutron-activated 
141Cer NM-212 (Molina et al. 2014). Moreover, dissolu-
tion of Ceria within alveolar macrophages or other extra-
cellular fluids, and subsequent absorption/bioavailability 
Fig. 6  Biokinetics of lung (a–c) and lymph node burdens (c) in the 
short-term study with 4 weeks of exposure. Lung burden after expo-
sure to 0.5 mg/m3 (a), 5 mg/m3 (b), and 25 mg/m3 (c) Ceria NM-212 
and burden of lung-associated lymph nodes after exposure to 25 mg/
m3 Ceria NM-212 (c, green) after 4 weeks of exposure and during 
129 days post-exposure
Fig. 5  a Microscopic appearance of lungs (a–d) in the short-term 
study with 4 weeks of exposure. a Control, lung; b 2 days after the 
end of exposure to 25 mg/m3 Ceria NM-212: lung, alveolar histiocy-
tosis with particles; c, d 34 days after the end of exposure to 25 mg/
m3 Ceria NM-212: lung, granulomatous inflammation. b Microscopic 
appearance of lungs (e, f) in the short-term study with 4 weeks of 
exposure; e control, BALT; f 34 days after the end of exposure to 
25 mg/m3 Ceria NM-212: BALT macrophage aggregates with par-
ticles. c Microscopic appearance of lung-associated lymph nodes 
(g, h) in the short-term study with 4 weeks of exposure; g control, 
lymph node; h 34 days after the end of exposure to 25 mg/m3 Ceria 
NM-212: tracheobronchial lymph node, macrophage aggregation 
with particles
◂
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of ionic Cerium into the blood and transport to extrapul-
monary organs, may occur (Oberdörster et al. 2005). The 
exploration in simulant fluids indicated structural changes 
mediated by marginal solubility in (acidic) PSF, but not in 
(neutral) PBS (see Table 1). Hence, there is only a minor, if 
any, contribution of ionic Cerium.
Local effects
Local pulmonary effects after inhalation of nano-Ceria 
were consistent after 5 days and 4 weeks of exposure. The 
reported pulmonary inflammation was assessed by the 
changes in BALF parameters (e.g., neutrophils) and his-
topathological findings (alveolar histiocytosis and granu-
lomatous inflammation).
In BALF, proinflammatory cytokines are also indi-
cators of an inflammatory process in the lung (Hender-
son 1984). Increased activities of the enzymes ALP and 
NAG indicated the proliferation of pneumocyte type II 
cells and activation of macrophages, respectively (Hen-
derson 2005; Capelli 1997). Consistently, the chemokine 
MCP-1 released by macrophages was concentration-related 
increased indicating a recruitment of blood monocytes 
into the alveolar compartment. The pro-inflammatory and 
neutrophil-attractant chemokine CINC-1 were increased in 
parallel but did not exceed MCP-1. Both parameters were 
assessed as predictive markers for early pulmonary inflam-
mation and macrophage recruitment into the lungs in pre-
vious inhalation studies testing 14 different nanomaterials 
(Landsiedel et al. 2014). However, MCP-1 was the only 
cell mediator, which could be correlated with the progres-
sion of alveolar histiocytosis in histopathology. Consist-
ently to ascending gradings and incidences in histopathol-
ogy after 4 weeks exposure, MCP-1 levels were higher 
increased after 4 weeks than 5 days of exposure. The other 
cell mediators were not able to predict or indicate any of 
the observed morphological changes. The cytokine M-CSF 
is a marker for the differentiation of monocytes into histio-
cytes. Produced by macrophages, it may be responsible for 
increases in macrophage numbers (Landsiedel et al. 2014), 
but was not increased overall. Osteopontin is known to be 
involved in pulmonary granuloma development in rodents 
(Chiba et al. 2000), but was not increased in our studies, 
although a granulomatous inflammation was observed.
In BALF, macrophages counts were not elevated sig-
nificantly. However, increase in alveolar macrophage 
number, different stages of (recruited, activated, highly 
particle loaded, destroyed) macrophages, and granuloma-
tous inflammation was apparent in histopathology. This 
discrepancy between macrophage numbers in BALF and 
histopathology during an inflammatory state in the lungs 
was already recognized in different other inhalation stud-
ies (Porter et al. 2002, 2007). Most probably, the lung 
macrophages were not detached and washed out using 
the lavage technique with only two washes in our studies 
(Henderson 2005). Other studies with Ceria reported higher 
macrophage counts in BALF using the same or a higher 
number of washes (Gosens et al. 2013; Ma et al. 2011). 
The BAL method used in the here-presented studies is 
highly standardized and yields highly reproducible results 
compared to more rigorous lavage techniques but is obvi-
ously not capable of detaching more sessile macrophages 
of the lung. Hence, neutrophil counts in BALF were used 
as sensitive parameter to indicate an inflammatory response 
(Henderson 2005; Henderson et al. 1979a, b).
Fig. 7  Dose–response curves using different dose metrics after 
5 days of exposure to 0.5 and 25 mg/m3 Ceria NM-211 and 0.5, 5, 
and 25 mg/m3 Ceria NM-212; a mass, b surface, c volume
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In pathology, lung weights were increased in the studies 
with 5 days (25 mg/m3 Ceria NM-211) and 4 weeks (5 and 
25 mg/m3 Ceria NM-212) of exposure. By light micros-
copy, Ceria particles were primarily seen extracellularly 
and intra-alveolar or engulfed by alveolar macrophages. 
Different to observations after inhalation to other nanopar-
ticles such as Titania, Ceria was not detected within alveo-
lar epithelial cells in the current study (Warheit and Hart-
sky 1993). This supports the hypothesis that macrophage 
activation and immobilization together with cytokine and 
fibrogenic effects may be the mode of action for micro-
scale Ceria inhalation toxicity [Environmental Protection 
Agency (EPA) 2009]. Furthermore, apoptosis of alveolar 
macrophages, their stimulation (pro-inflammatory cytokine 
and ROS release), and switch from the inflammatory M1 to 
a fibrotic M2 type was shown by the interaction of nano-
Ceria with these cells after an intratracheal instillation 
study with rats (Ma et al. 2011).
At the lowest concentration of 0.5 mg/m3 in the present 
studies, the histopathological findings alveolar histiocytosis 
and particles, either free or within macrophages, reflect an 
expected physiological response (Brain et al. 1976). How-
ever, after 4 weeks of exposure, the alveolar histiocytosis 
had progressed to a multifocal granulomatous inflammation 
at 5 mg/m3 and at 25 mg/m3 within 4 weeks after the end of 
exposure. The combination of moderate alveolar histiocy-
tosis with particles and the presence of eosinophilic mate-
rial, potentially precursors of granulomatous inflammation, 
are thus considered to be adverse. Granulomatous inflam-
mation, multifocal microgranulomas, or granulomas due to 
inhalation of nano-Ceria have previously been reported in 
a number of animal studies (Srinivas et al. 2011; Cho et al. 
2010; Snipes 1989; Aalapati et al. 2014). Granulomatous 
inflammation represents one type of chronic inflammation 
which is characterized by inflammatory lesions with large 
numbers of macrophages forming interlacing palisades, 
lymphocytes, and plasma cells (Renne et al. 2009). Other 
cells of the mononuclear phagocyte system (epithelioid 
and multinucleated cells) also contribute to maintain the 
inflammatory process. However, in the present studies, later 
stages of granuloma formation, transformation of mac-
rophages to epithelioid, or giant cells were not observed. 
However, granulomatous inflammation can lead to tissue 
damage and fibrosis at later stages as observed by Ma et al. 
4 weeks after a single intratracheal instillation of 7 mg/kg 
nano-Ceria in rats (Ma et al. 2014).
Concerning the two different methods (BAL and histo-
pathology) in the study with 4 weeks of exposure, BALF 
parameters showed a regression during the post-exposure 
period. Histopathological findings, in contrast, progressed 
after the end of the exposure at concentrations of 5 mg/m3 
Ceria and above. A regression of the BALF parameter (e.g., 
neutrophils) and a certain progression of histopathological 
findings during the post-exposure were already recognized 
in previous works with Ceria (Gosens et al. 2013; Srini-
vas et al. 2011). It was concluded that during a sustained 
inflammation in the lungs, parameters in BALF do not rep-
resent the current inflammatory state and damage in the 
lungs.
Lymphatic clearance of inhaled Ceria via the lymphatic 
vessels from the pulmonary region to the lung-associated 
lymph nodes was demonstrated by histological evaluations 
and confirmed by measured Cerium lymph node burdens. 
Accumulation of free particles or particles within mac-
rophage aggregates was detected in the BALT or mediasti-
nal and tracheobronchial lymph nodes. Increasing Cerium 
clearance into the lung-associated lymph nodes was cor-
related with an increase in grading and severity of mac-
rophage aggregates during the post-exposure period (see 
pathological score, Table 4). Moderate macrophage aggre-
gates with particles in the lung-associated lymph nodes, 
combined with lympho-reticulocellular hyperplasia, were 
considered to be adverse. It is more likely that the particles 
reached the associated lymph nodes by phagocytizing mac-
rophages than by entering the interstitium.
Aerosol concentrations of 5 and 25 mg/m3 caused 
inflammatory effects in the lung, which can be considered 
adverse. At 0.5 mg/m3, slight effects were still detected by 
BALF after 5 days of exposure but not by histopathology or 
after 4 weeks of exposure. BALF parameters proved to be 
more sensitive to short-term effects but less predictive for 
the progression of these effects.
The observations of the current study resemble the find-
ings of previously published inhalation (and instillation) 
studies with different Ceria (Gosens et al. 2013; Ma et al. 
2011; Demokritou et al. 2012; Aalapati et al. 2014). In 
an 28-day inhalation study with the Ceria NM-212, Gos-
ens et al. (2013) observed pulmonary effects at an aero-
sol concentration equivalent to 2.5 mg/m3. These effects 
were less pronounced compared to the current study. The 
dose-equivalent concentration of 2.5 mg/m3 was achieved 
by the exposure of the animals to 50 mg/m3 for different 
daily exposure durations, whereas the studies reported 
here exposed animals to actual 0.5, 5, and 25 mg/m3 for 
6 h/day. The difference in daily exposure times and dose 
rate may account for the differences in the severity of the 
effects. Aalapati et al. (2014) observed pulmonary inflam-
mation, necrosis, fibrosis, and granulomas in the lung of 
mice exposed to 2 mg/m3 nano-Ceria for 14 and 28 days 
resulting in a burden of 1,200 mg/g lung after exposure for 
28 days. Rats exposed for 4 weeks in the study reported 
here inhaled 12.5-fold higher aerosol concentrations, which 
yielded a lung burden of around 3,000 µg/lung (equiva-
lent to 2,730 µg/g lung) and resulted in less morphological 
changes. The results of the 2 mg/m3 Ceria inhalation study 
to mice leave open questions which need to be discussed.
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Systemic effects
Substance-related adverse effects after inhalation expo-
sure to two Ceria in the short-term studies were limited 
to the lung. Potential systemic genotoxicity was assessed 
by micronuclei test (MNT). The MNT is a frequently used 
genotoxicity test on nanomaterials (Oesch and Lands-
iedel 2012). This in vivo assay is able to demonstrate the 
potential interaction of nanomaterials with chromosomes 
or mitotic apparatus of replicating erythroblasts as well 
as their influence on erythropoiesis in the bone marrow 
(LeBaron et al. 2013). No genotoxic potential after inha-
lation of Ceria NM-211 or NM-212 was observed in both 
short-term studies. Cerium bone marrow content was not 
determined in our inhalation studies, but a tissue concentra-
tion of 6.61 ng/g bone marrow was reported 7 days after 
intratracheal instillation of 1 mg/kg of neutron-activated 
Ceria NM-212 (Molina et al. 2014). Ceria inhalation expo-
sure has been reported to result in a wide range of systemic 
responses ranging from no effects to severe effects in blood 
or extrapulmonary organs, such as liver or kidneys (Aala-
pati et al. 2014; Gosens et al. 2013; Srinivas et al. 2011). 
In the study reported here, 5 days of exposure to 25 mg/m3 
(retained lung burden of 0.53 mg) resulted in higher abso-
lute and relative neutrophil cell counts in the blood, with-
out an increase in total cell counts. This slight neutrophilia 
was detected directly after the end of exposure and was no 
longer present after 3 weeks of post-exposure. Consider-
ing the pronounced inflammation in the lung at 25 mg/m3, 
the neutrophilia in blood was considered to be secondary 
to the local effects (systemic acute-phase response). The 
inflammatory response in the lung based on the increase 
in neutrophil counts in BALF was also lower after 4 weeks 
compared to 5 days of exposure. And no altered blood 
parameters could be detected after 4 weeks of inhalation 
exposure. Furthermore, a whole panel of extrapulmonary 
organs and tissues was examined histologically as required 
by OECD test guideline 412. Very low Cerium contents 
were detected in the liver at two time points after 4 weeks 
of inhalation exposure to 25 mg/m3 Ceria NM-212 (which 
is a general finding for inhaled nanoparticles) without any 
related morphological abnormalities. None of the other 
extrapulmonary organs showed any morphological abnor-
malities. The absence of systemic effects is consistent with 
the very low extrapulmonary tissue Ceria concentrations 
in this and other studies (Gosens et al. 2013; Geraets et al. 
2012; Molina et al. 2014). After instillation of 1 mg/kg 
body weight neutron-activated 141Cer NM-212, only 0.3 % 
of the administered dose was found in the liver after 28 days 
post-instillation (Molina et al. 2014). However, after a sin-
gle intravenous (i.v.) administration of 30 nm nano-Ceria 
(87 mg/kg body weight) into rats, oxidative stress was seen 
in liver and spleen and granulomas were observed in the 
liver (Yokel et al. 2012). The Ceria-induced adverse effects 
were explained by mechanical irritation or its chemical 
(catalytic) activity (Yokel et al. 2012). The high Cerium 
concentrations in the liver after i.v. administration were 
far beyond the concentrations achievable by oral, dermal, 
or inhalation exposure. In contrast, severe systemic find-
ings were reported in mice after 28-day inhalation expo-
sure to 2 mg/m3 nano-Ceria plus 28 days of post-exposure 
(lung burden of 500 mg/g tissue). The findings comprised 
necrosis in kidneys, hepatocytomegaly, and cytoplasmatic 
vacuolization in the heart (Aalapati et al. 2014), which was 
claimed to be associated with moderate accumulation of 
Cerium in extrapulmonary organs. However, even i.v. injec-
tion of high doses of Ceria did not lead to similar changes 
in rat kidney and heart (Yokel et al. 2012).
Comparison of NM-211 with NM-212
The effects of two different Ceria (NM-211 and NM-212) 
were compared after 5 days of inhalation exposure. Ceria 
NM-211 and NM-212 have identical composition, agglom-
eration state, crystallinity, and insolubility. Compared to 
Ceria NM-212, NM-211 has considerably smaller primary 
particles, larger specific surface, significantly fewer organic 
contaminations on the surface, and reduced photocatalytic 
activity. Despite these differences, Ceria NM-211 and 
NM-212 share the same tendency to recrystallize in acidic 
PSF, which simulates the lysosome of macrophages. These 
properties are comparable to each other, but significantly 
different from other metal oxide nanomaterials and seem 
to be primarily substance-related themselves. Compared 
to Ceria NM-212, Ceria NM-211 elicited higher increases 
in lymphocytes, cell mediators (e.g., MCP-1), and neutro-
phils in BALF at 25 mg/m3 with a slower recovery during 
the post-exposure period. Moreover, significant increase 
in lung weights was noted in animals exposed to 25 mg/
m3 Ceria NM-211, but not NM-212. When biological 
effects (e.g., inflammation) of two particles are compared, 
the lung burden may be more appropriately expressed as 
particle volume, particle surface area (Oberdorster et al. 
1994b). Morrow first introduced volume as dose metric for 
overload (Morrow 1988). Pauluhn modified the overload 
hypothesis by introducing agglomerate density (instead of 
physical density) into the calculation of volumetric loading 
(Pauluhn 2011). The effective particle density is needed to 
calculate the particle volume. In a guidance document pub-
lished by Webb (2001), various definitions of the powder 
volumes are given (e.g., apparent density and tapping den-
sity). In the current study, an agglomerate density of 2 g/
cm3 for NM-212 and 0.6 g/cm3 for NM-211 was selected. 
The densities were extracted by integrating the porosity 
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below 1 µm (from Hg intrusion porosimetry) and then 
derived empirically by approaching MPPD model calcula-
tions together with measured mass lung burden. Accord-
ing to our calculation, volumetric lung overload can only 
be assumed after 4 weeks exposure to 25 mg/m3. Impaired 
lung clearance—which is one of the consequences of lung 
overload conditions—was, however, already observed after 
inhalation of 5 mg/m3 Ceria.
It is not fully understood which characteristics of nano-
Ceria lead to the effects observed in previous and current 
studies [Environmental Protection Agency (EPA) 2009]. 
Assessing the immune toxicity of another member of the 
group of poorly soluble particle namely Titania after instil-
lation in rats, lower phagocytic ability and disruption of 
pulmonary alveolar macrophage function were correlated 
with surface reactivity and size of surface area (Liu et al. 
2010). A number of studies over the past 15 years suggested 
that the smaller the particle size (the greater the surface 
area dose), the greater the induced inflammatory response 
(Oberdorster et al. 1994a; Cullen et al. 2000; Sager and 
Castranova 2009; Sager et al. 2008). Furthermore, surface 
area of retained particles seems to correlate with acute 
inflammatory reactions after inhalation. The correlation of 
lung burden, expressed as mass, volume, and surface area, 
and neutrophil (PMN) counts in BALF as parameter for 
biological effects is presented in Fig. 7 (Table S9).
In the present study with 5 days of exposure, the larger 
specific surface area of Ceria NM-211 seems to contrib-
ute to the higher biological activity as compared to Ceria 
NM-212. Surface area normalized the dose response of the 
two Ceria materials. This result is consistent with other 
studies, which used surface area as dose metric to quantify 
the toxicity of the PSPs Titania and barium sulfate (Tran 
et al. 2000; Oberdorster et al. 1994a, b).
Comparison of 5 days and 4 weeks of exposure
Rats were exposed to Ceria NM-212 for 5 days and 
4 weeks. Exposure to 25 mg/m3 for 5 days resulted in the 
same lung burden as 4 weeks of exposure to 5 mg/m3. In 
consideration of the same lung burdens, the dose rates 
are 106 µg (5 days of exposure to 25 mg/m3) and 26 µg/
day (4 weeks of exposure to 5 mg/m3) (see Table 5). One 
should note that the calculated dose rates still include the 
clearance and, therefore, reflect rather the retained than the 
deposited Ceria concentration in the lung.
The dose rate of particles seems to influence the acute 
inflammatory reaction in the lung (Baisch et al. 2014). 
Despite the same lung burdens but different dose rates, a 
stronger neutrophil response in BALF was observed after 
the shorter exposure time (Figs. 8, 9). The decay in neu-
trophil numbers after 4 weeks was by far slower than after 
5 days, suggesting that inflammation developing at lower 
dose rate is longer lasting and more persistent. Moreover, 
BALF effects almost completely regressed after the end of 
the 5 days exposure to 5 mg/m3 even though the lung bur-
den was only cleared by about 10 % (Fig. 9).
Hence, the dose rate rather than the lung burden seems 
to drive the neutrophil count in BALF (Fig. 9; Table 5).
Neutrophils are one of the first cell types recruited by 
inflammatory signals evoked by deposited particles in the 
lung, with peak numbers within 48 h (Alber et al. 2012). 
Neutrophils in BALF are a sensitive measure of this initial 
phase. With sustained inflammatory conditions, neutrophil 
recruitment undergoes a certain physiological adaptation 
in the body. The number of neutrophils observed in BALF 
was decreasing and supplemented by mononuclear cells, 
especially macrophages that were visible in histopathol-
ogy but not in BALF. The sustained presence of particles 
in the lung can drive macrophages to form granulomatous 
lesions. Although a small dose rate over a long exposure 
time achieved the same lung burden as a high dose rate 
over a short time period, the effects observed may be more 
severe due to consistent irritation of the tissue by small 
dose rates of fresh materials. Apparently, the initial neutro-
phil reaction is directed by the dose rate while the progres-
sion of the inflammation in the lung is also driven by the 
continuing presence of particles in the lung.
Conclusion
Inhaled nano-Ceria was deposited in the lung. The par-
ticles were cleared from the lung with a retention half-
time of 40 days at a concentration of 0.5 mg/m3; higher 
aerosol concentrations impaired this clearance. A smaller 
Table 5  Dose rate of Ceria 
NM-212
a
 Lung burden values after 
5 days of exposure (5 days 
exposure) and 2 days after 
the end of exposure (4 weeks 
exposure)
Study Test substance Concentration (mg/m3) Lung burdena (µg) Dose rate (µg/day)
5 days (5 exposures) Ceria NM-212 0.5 11 2.2
5 100 20
25 530 106
4 weeks (20 exposures) Ceria NM-212 0.5 41 2.05
5 520 26
25 2,620 131
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fraction of the particles was transferred to the lung-asso-
ciated lymph nodes. The initial inflammatory reaction 
was observed by an increase in neutrophils which corre-
lated with dose rate rather than absolute lung burden. With 
time, the neutrophil number decreased. The decrease was 
observed after the exposure ended but also with sustained 
exposure (longer than 5 days in the current studies). In the 
later phase (after 4 weeks of exposure), the inflammatory 
reaction was dominated by mononuclear cells, especially 
macrophages. The inflammatory response was driven by 
the surface of the particles presented to the lung, as this was 
the dose metrics with the best correlation of the two Ceria 
materials. An aerosol concentration of 0.5 mg/m3 did not 
cause inflammatory responses in the lung. 5 mg/m3 was the 
lowest aerosol concentration at which the early as well as 
the later inflammatory response was observed, even though 
lung burdens were different at the onset of the two phases. 
The progression of the later inflammatory reaction toward a 
granulomatous type depended on the duration and amount 
of the particle (surface) burden in the lung (Fig. 10). Thus, 
the potency of an inhaled particle to induce inflammatory 
responses in the lung could be assessed by the aerosol con-
centration causing the initial neutrophil response, whereas 
the later granulomatous phase could only be detected by 
histopathology. The further progression of the biological 
response was determined by the continuing presence of the 
particles in the lung. Ultimately, the further progression of 
the biological responses needs to be studied by the long-
term inhalation study assessing the effects as well as the 
time course of the lung burdens. The results of the short-
term studies presented here were used to set the aerosol 
concentrations of the long-term study with Ceria which is 
currently being performed. Four aerosol concentrations are 
being tested, 0.1, 0.3, 1, and 3 mg/m3, expected to result 
in no inflammation and no overload (two concentrations), 
Fig. 8  Inflammatory potency of the short-term studies with 5 days 
and 4 weeks of exposure over post-exposure period: absolute neutro-
phil counts in BALF in the short-term studies: 3 and 24 days after end 
of exposure to 25 mg/m3 Ceria NM-211 (orange 5-day exposure) and 
NM-212 (light blue 5-day exposure) or one and 35 days after the end 
of exposure to 25 mg/m3 NM-212 (dark blue 4-week exposure)
Fig. 9  Neutrophil counts in BALF correlated with deposited particle 
per surface lung after 5-day and 4-week exposure using the aerosol 
concentrations of 0.5, 5, and 25 mg/m3 CeO2 NM-212 for each point
Fig. 10  Summary of results 
after 5 days and 4 weeks of 
exposure to Ceria
5 day 4 week 4 week
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inflammation without overload, and inflammation and 
overload, respectively.
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